Gerben Zondag
About
Gerben Zondag is from Netherlands. Gerben is currently Immunetune founder & COO at Immunetune BV, located in Leiden, South Holland, Netherlands. Gerben also works as CEO at Synvolux Therapeutics B.V., a job Gerben has held since Sep 2015. Another title Gerben currently holds is Vice President Technology Affairs at VitalNext B.V.. In Gerben's previous role as a CEO at Immunetune, Gerben worked in Leiden, the Netherlands until Sep 2021. Prior to joining Immunetune, Gerben was a Business Development & Commercialisation Advisor at Leiden University and held the position of Business Development & Commercialisation Advisor at Leiden. Prior to that, Gerben was a Business Developer at Leiden University Medical Center, based in Leiden from Aug 2011 to Sep 2014. Gerben started working as Director and co-founder at Swan Diagnostics in Aug 2010. From Jan 2009 to Jul 2011, Gerben was VP Technology Affairs at DNage BV. Prior to that, Gerben was a Director of Research at DNage, based in The Hague Area, Netherlands from Apr 2006 to Dec 2008.
If you’re looking for Gerben Zondag's email address, you can find it on finalscout.com. Finalscout is a professional database with more than 500 million business professionals and 200 million company profiles.
Gerben Zondag's current jobs
Synvolux is a Dutch, privately owned company that develops breakthrough methods for synthetic DNA production, and markets highly efficient, non-viral transfection reagents for intracellular delivery of DNA, RNA(i), peptides, and proteins. Its RMADA™ platform allows cell-free, rapid, scalable and error-free production of DNA. SAINT™ technology is based on a panel of proprietary, entirely synthetic lipid structures that have been demonstrated to be safe, non-toxic, and broadly applicable for both research and clinical applications. Synvolux has a broad, international customer base, active programs in the field of DNA and mRNA vaccines, and is open to discuss partnerships.
VitalNext brings together the worlds of Life Sciences and consumer products. Healthy Ageing is an important topic in most societies throughout the world. The increasing life expectancy of most people creates a demand for products that keep us in good health for prolonged periods of time. Besides the classical approach of ‘curing disease when it arises’, the importance of lifestyle and nutrition in prevention of disease is now widely recognized, but still grossly underestimated. VitalNext develops proprietary nutritional products with evidence-based health benefits through extensive research and clinical testing within our own network and through collaborations with our research partners. These products are commercialized via distribution agreements with specialized business partners.
Sequrex offers professional and independent support and consultancy services in the field of Life Sciences. With over 20 years of experience in both academic and corporate settings and a large network of experts, Sequrex supports both start-ups and established companies, research institutions, NGOs, and government bodies in various aspects of Life Sciences. Please visit www.sequrex.com for more information.
Gerben Zondag's past jobs
Immunetune, a pioneering biotech company based in Leiden (the Netherlands), is developing personalized DNA-based vaccines to treat highly mutated cancer types. In close collaboration with the Leiden University Medical Center, we develop vaccines that train the immune system to selectively identify and eliminate tumor cells based on tumor-specific DNA mutations (neoantigens), thus yielding a type of precision medicine with an excellent safety profile.
Scouting, IP protection, and licensing of innovative research emerging from Leiden University and its Medical Center
Technology scouting, patenting, commercialization, licensing, research collaborations, spin-off company formation
Ageing research